*	OR T2 T3
R1	Has_value Arg1:T4 Arg2:T5	
R2	Has_qualifier Arg1:T6 Arg2:T7	
*	OR T16 T15
R3	Has_qualifier Arg1:T14 Arg2:T16	
R4	Has_value Arg1:T18 Arg2:T19	
R5	Has_value Arg1:T20 Arg2:T21	
*	OR T24 T25
R6	Has_qualifier Arg1:T24 Arg2:T27	
R7	Has_context Arg1:T23 Arg2:T22	
R8	AND Arg1:T23 Arg2:T24	
R9	AND Arg1:T23 Arg2:T20	
R10	Has_qualifier Arg1:T6 Arg2:T8	
R11	Has_qualifier Arg1:T6 Arg2:T9	
R12	Has_qualifier Arg1:T6 Arg2:T10	
T1	Non-query-able 0 324	Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, willingness and ability to complete collection of data via wearable device and study mobile must be obtained and documented according to the local regulatory requirements
T2	Person 327 333	Female
T3	Person 337 341	male
T4	Person 353 356	Age
T5	Value 357 371	= 18 years old
T6	Condition 438 451	breast cancer
T7	Qualifier 385 393	invasive
T8	Qualifier 374 384	Metastatic
T9	Qualifier 394 419	hormone receptor positive
T10	Qualifier 424 437	HER2 negative
T12	Non-query-able 453 477	histologically confirmed
T13	Non-query-able 481 800	Patients who in the opinion of the treating physician are candidates suitable for randomization for mono-chemotherapy treatment, that has either an approved label in Europe and/or is supported by guidelines for the treatment of first-line advanced BC, which are based on evidence on safety and efficacy in this setting.
T14	Condition 830 854	metastatic breast cancer
T15	Qualifier 817 829	asymptomatic
T16	Qualifier 802 813	Symptomatic
T18	Observation 1096 1111	Life-expectancy
T19	Value 1112 1122	> 6 months
T20	Measurement 950 971	NCI CTCAE version 4.0
T21	Value 972 981	grade = 1
T22	Observation 857 867	Resolution
T23	Condition 875 894	acute toxic effects
T24	Procedure 904 923	anti-cancer therapy
T25	Procedure 927 945	surgical procedure
T27	Qualifier 898 903	prior
T28	Negation 983 989	except
T29	Condition 990 998	alopecia
T30	Non-query-able 983 1093	except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion)
T31	Pregnancy_considerations 1126 1419	or female patients: The patients need to be either A) of non-childbearing potential (documented postmenopausal or post hysterectomy) B) childbearing potential with negative serum or urinary pregnancy test (in this case patients need to use highly effective non-hormonal contraceptive methods).
